Publications: 1,448 in 2026-03. -3.5% share of all MeSH-indexed PubMed records vs the same month last year (1,530 in 2025-03).
PublicationsPubMed
1,4482026-03
-3.5% share of all MeSH-indexed PubMed records vs same month last year (1,530 in 2025-03)provisional · settling
1.27% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 130 in 2026-08. +23.8% vs the same month last year (105 in 2025-08).
Clinical trialsClinicalTrials.gov
1302026-08
+23.8% vs same month last year (105 in 2025-08)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 617 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 617 is in the 83rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
6172026-08
83rd percentilerunning high, versus 15-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 65 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 65 is in the 73rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
652026-08
73rd percentilerunning high, versus 15-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 81 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 81 is in the 33rd percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
812026-08
33rd percentilein its typical range, versus 15-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 1,448 is in the 58th percentile, in its typical range, versus 320 months since 2000.
58thpercentile
in its typical range
1,448/mo · higher than 57% of 320 months since 2000
Clinical trials
Clinical trials: latest count 130 is in the 99th percentile, near its historical high, versus 320 months since 2000.
99thpercentile
near its historical high
130/mo · higher than 98% of 320 months since 2000
NIH grantsprovisional
NIH grants: latest count 617 is in the 83rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
83rdpercentile
running high
617/mo · higher than 80% of 15-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 65 is in the 73rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
73rdpercentile
running high
65/mo · higher than 67% of 15-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 81 is in the 33rd percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
33rdpercentile
in its typical range
81/mo · higher than 27% of 15-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 15 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 320 mo; NIH grants 2025 to 2026 · 15 mo; Patents 2025 to 2026 · 15 mo; Preprints 2025 to 2026 · 15 mo.
Publications2000 to 2026 · 320 mopeak 3,123/mo
Clinical trials2000 to 2026 · 320 mopeak 140/mo
NIH grants2025 to 2026 · 15 mobackfill pendingpeak 797/mo
Patents2025 to 2026 · 15 mobackfill pendingpeak 89/mo
Preprints2025 to 2026 · 15 mobackfill pendingpeak 108/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2023-07..2026-06
6%of works have an industry affiliation
Triphase (Belgium)82
Inserm78
Harvard University62
Centre National de la Recherche Scientifique35
The University of Texas Southwestern Medical Center32
Clinical trials
Lead sponsors · 2023-09..2026-08
34%industry-led in 2026-08
Novo Nordisk A/SIndustry90
Eli Lilly and CompanyIndustry76
Cairo UniversityAcademic/other71
AmgenIndustry24
AstraZenecaIndustry24
NIH grants
Funded institutions · 2025-06..2026-08
5,686awards in window
UNIVERSITY OF MICHIGAN AT ANN ARBORMI · $51.6M · R01/P30126
WASHINGTON UNIVERSITYMO · $63.9M · R01/P30119
COLUMBIA UNIVERSITY HEALTH SCIENCESNY · $71.8M · R01/P30117
UNIVERSITY OF ALABAMA AT BIRMINGHAMAL · $72.6M · R01/P30114
BAYLOR COLLEGE OF MEDICINETX · $53.1M · R01/P01113
2026-08-31biorxivUniversity of Texas Health Science Center at Houston
Organizations only. No person data.
Would you read a monthly digest for Obesity?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Obesity. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Obesity.
How we map "Obesity"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Obesity"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10